Tag: Debate

Categories
Business

Slate Suspends Mike Pesca of “The Gist” After Debate Over Racial Slur

Slate Suspends Mike Pesca of "The Gist" After Debate Over Racial Slur

The online publication Slate has suspended a well-known podcast host after discussing with colleagues whether people who are not black should be able to quote a racist Slur in certain contexts.

Mike Pesca, the host of “The Gist,” a podcast about news and culture, said in an interview that he was suspended indefinitely on Monday after defending the use of the arc in certain contexts. He argued last week during a conversation with colleagues on the Slack interoffice messaging platform.

In a long line of messages, Slate staff discussed the resignation of Donald G. McNeil Jr., a reporter who said this month he had resigned from the New York Times after holding the arc during a discussion on racism at work had used as a guide for a student trip in 2019.

Mr Pesca, who is white, said he felt there were contexts in which the arc could be used, as shown in screenshots of the Slack conversation shared with The Times. Dan Check, Slate’s general manager, stepped in to end the discussion.

Katie Rayford, Slate’s spokeswoman, confirmed that “The Gist” had been suspended pending an investigation but did not want to comment on Mr. Pesca. “While I cannot address certain allegations that are being investigated,” Ms. Rayford said, “I can confirm that this was not a decision based on an isolated abstract argument on a Slack channel.”

Defector Media, a digital outlet focusing on sports and culture, previously reported on the suspension of Mr Pesca and the internal debate at Slate.

Mr Pesca investigated the dispute over the use of the bow in a 2019 podcast about a black security officer who was fired for its use. In a recording of the episode, Mr Pesca said he used the term while quoting the man but asked his producer to do a version without the term. After consulting with his producers and supervisor who protested his quote of the bow, they decided to use the version without it, he said.

“The version of the story with the offensive word was never aired and that’s how I think the editorial process should go,” Pesca said in an interview.

No action was taken against him following an investigation by the human resources department into his quote from the arch, Pesca said. He said he apologized to the producers involved.

In November 2019, Slate introduced a policy that requires podcast presenters and producers to discuss the use of racial terms in an upcoming episode in or from quoted material before it is recorded.

Mr Pesca said Mr Check, the executive director, and Jared Hohlt, editor-in-chief of Slate, raised the previous instance of his citing the sheet when they spoke to him after speaking with Slack. He added that they had mentioned another case where he used the term which he did not remember.

Mr Pesca, whose interview style at times seemed to epitomize Slates’ contrary brand, said he was told on Friday that he would be suspended for a week without pay. He was told on Monday the suspension was indefinite, he said.

Mr Pesca, who has worked at Slate for seven years, said he had “heart disease” for hurting his colleagues but added, “I hate the idea of ​​things that cannot be discussed and things that cannot be said can.”

Jacob Weisberg, Slate’s former chairman and editor-in-chief, who left the company in 2018 for the podcast start-up Pushkin, described Mr. Pesca as “a great talent and a fair journalist”.

“I don’t think he did anything that deserves discipline or consequence, and I think it’s an example of some kind of overreaction and lack of judgment and perspective that is unfortunately spreading,” said Weisberg.

Joel Anderson, a black Slate employee who hosted the third season of the Slow Burn podcast, disagreed. “It is an extremely small question for black employees not to hear that particular bow and not debate whether it is okay for white employees to use that particular bow,” he said.

Categories
Business

China Blocks Clubhouse App After Temporary Flowering of Debate

China Blocks Clubhouse App After Brief Flowering of Debate

It is unclear how many Chinese users were registered in the clubhouse in the mainland. While it was unlocked, the app was only available on Apple’s operating system, making it inaccessible to the vast majority of Chinese people who use Android. Users had to switch from Apple’s China App Store to download Clubhouse.

The app is also only available by invitation, which has led to a small black market for invitation codes in recent days. Before the app was blocked, the price of a code was up to 300 yuan, or around $ 46.

That didn’t stop thousands of Chinese users from flocking to the platform, which has audio chat rooms that disappear when the conversations are over. In the past few days, several Chinese language chat rooms with a capacity of 5,000 users have been occupied. Some said they would connect from the mainland while others identified as Chinese based overseas. Many said they were from Hong Kong and Taiwan.

Apparently every topic on China’s censorship blacklist had been discussed. In a chat room, participants discussed which Chinese leaders were responsible for Tiananmen Square in 1989. In another chat, users shared their experiences with the Chinese police and security guards.

In a third case, participants sat in silence as they mourned the first anniversary of the death of Li Wenliang, the doctor reprimanded for warning of the coronavirus in Wuhan, China. He died of the same disease, and his death caused the hashtag “freedom of speech” to spread widely on Chinese social media.

The app’s sudden popularity in China had led many to wonder how long the party’s government would give the party a lifetime. Social media companies operating in China are required to monitor user identity, share data with the police, and adhere to strict censorship guidelines.

Most of the major Western news sites and social media apps like Twitter, Facebook, and Instagram are completely blocked in China, and access to VPNs on the mainland is becoming increasingly difficult. The domestic social media platforms approved in China, such as WeChat and Weibo, are strictly regulated and monitored by censors.

Categories
Business

Pinduoduo Worker Deaths Ignites China Debate Over Work

Pinduoduo Employee Deaths Ignites China Debate Over Work

Lyu Xiaolin, an employee of a large Chinese tech company, said she had discussed the Pinduoduo deaths at length with colleagues who agreed that the idea of ​​unbearable work pressure was all too familiar.

“The conclusion was that this is too terrible and we need to cherish our own lives,” she said. “We should make sure we leave work earlier in the future.”

She herself had changed roles in her company, which she did not want to identify for fear of retaliation because her previous work often meant that she had to work until 11 or 12 a.m., sometimes even until 3 a.m. She was looking for therapy to alleviate the psychological stress.

China’s hypercompetitive work culture, especially in the tech world, has been a frequent cause of concern and criticism in recent years. While many once celebrated growth at all costs as the engine of China’s development, young workers have increasingly complained about the cost to their health and personal relationships.

This dissatisfaction clearly exploded in 2019 when simple technicians organized a rare online protest against the so-called “996” culture – working days that last six days a week from 9 a.m. to 9 p.m. – and increased awareness of China’s labor law, the working days of more than eight hours without overtime pay is generally prohibited. However, companies insist that the long hours are voluntary and the authorities, aware of unofficial mobilization, censored much of the discussion about the movement. The internet went on.

The debate has broken out again.

On January 3rd, an anonymous user of Maimai, a professional networking platform, wrote that a friend of Pinduoduo died unexpectedly and blamed the company. The post gained traction, and Pinduoduo confirmed that a worker surnamed Zhang died on December 29th on her way home.

There was no public explanation for the cause of death, but many online have linked it to overwork. Users found that Ms. Zhang had been working on a new online grocery product that Pinduoduo had been promoting, and that the company’s executive director, Colin Huang, had just been named China’s second richest person.

Categories
World News

As Rollout Falters, Scientists Debate New Vaccination Techniques

As Rollout Falters, Scientists Debate New Vaccination Tactics

As governments around the world rush to vaccinate their citizens against the surging coronavirus, scientists are locked in a heated debate over a surprising question: Is it wisest to hold back the second doses everyone will need, or to give as many people as possible an inoculation now — and push back the second doses until later?

Since even the first shot appears to provide some protection against Covid-19, some experts believe that the shortest route to containing the virus is to disseminate the initial injections as widely as possible now.

Officials in Britain have already elected to delay second doses of vaccines made by the pharmaceutical companies AstraZeneca and Pfizer as a way of more widely distributing the partial protection afforded by a single shot.

Health officials in the United States have been adamantly opposed to the idea. “I would not be in favor of that,” Dr. Anthony S. Fauci, the nation’s top infectious disease expert, told CNN on Friday. “We’re going to keep doing what we’re doing.”

But on Sunday, Moncef Slaoui, scientific adviser of Operation Warp Speed, the federal effort to accelerate vaccine development and distribution, offered up an intriguing alternative: giving some Americans two half-doses of the Moderna vaccine, a way to possibly milk more immunity from the nation’s limited vaccine supply.

The rising debate reflects nationwide frustration that so few Americans have gotten the first doses — far below the number the administration had hoped would be inoculated by the end of 2020. But the controversy itself carries risks in a country where health measures have been politicized and many remain hesitant to take the vaccine.

“Even the appearance of tinkering has negatives, in terms of people having trust in the process,” said Natalie Dean, a biostatistician at the University of Florida.

The public rollout remained bumpy over the weekend. Seniors lined up early for vaccinations in one Tennessee town, but the doses were gone by 10 a.m. In Houston, the Health Department phone system crashed on Saturday, the first day officials opened a free vaccination clinic to the public.

Nursing home workers in Ohio were opting out of the vaccination in great numbers, according to Gov. Mike DeWine, while Mayor Eric Garcetti of Los Angeles, now a center of the pandemic, warned that vaccine distribution was moving far too slowly. Hospitalizations of Covid-19 patients during the past month have more than doubled in California.

The vaccines authorized so far in the United States are produced by Pfizer-BioNTech and Moderna. Britain has greenlit the Pfizer-BioNTech and Oxford-AstraZeneca vaccines.

All of them are intended to be delivered in multiple doses on a strict schedule, relying on a tiered protection strategy. The first injection teaches the immune system to recognize a new pathogen by showing it a harmless version of some of the virus’s most salient features.

After the body has had time to study up on this material, as it were, a second shot presents these features again, helping immune cells commit the lesson to memory. These subsequent doses are intended to increase the potency and durability of immunity.

Clinical trials run by Pfizer-BioNTech and Moderna showed the vaccines were highly effective at preventing cases of Covid-19 when delivered in two doses separated by three or four weeks.

Some protection appears to kick in after the first shot of vaccine, although it’s unclear how quickly it might wane. Still, some experts now argue that spreading vaccines more thinly across a population by concentrating on first doses might save more lives than making sure half as many individuals receive both doses on schedule.

That would be a remarkable departure from the original plan. Since the vaccine rollout began last month in the United States, second shots of the vaccines have been held back to guarantee that they will be available on schedule for people who have already gotten their first injections.

But in Britain, doctors have been told to postpone appointments for second doses that had been scheduled for January, so that those doses can be given instead as first shots to other patients. Officials are now pushing the second doses of both the Pfizer-BioNTech and Oxford-AstraZeneca vaccines as far back as 12 weeks after the first one.

In a regulatory document, British health officials said that AstraZeneca’s vaccine was 73 percent effective in clinical trial participants three weeks after the first dose was given and before the second dose was administered. (In cases in which participants never received a second dose, the interval ended 12 weeks after the first dose was given.)

But some researchers fear the delayed-dose approach could prove disastrous, particularly in the United States, where vaccine rollouts are already stymied by logistical hurdles and a patchwork approach to prioritizing who gets the first jabs.

“We have an issue with distribution, not the number of doses,” said Saad Omer, a vaccine expert at Yale University. “Doubling the number of doses doesn’t double your capacity to give doses.”

Federal health officials said last week that some 14 million doses of the Pfizer-BioNTech and Moderna vaccines had been shipped out across the country. But as of Saturday morning, just 4.2 million people in the United States had gotten their first shots.

That number is most likely an underestimate because of lags in reporting. Still, the figure falls far short of the goal that federal health officials set as recently as last month to give 20 million people their first shots by the end of 2020.

Covid-19 Vaccines ›

Answers to Your Vaccine Questions

With distribution of a coronavirus vaccine beginning in the U.S., here are answers to some questions you may be wondering about:

    • If I live in the U.S., when can I get the vaccine? While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help.
    • When can I return to normal life after being vaccinated? Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they’ll only be able to vaccinate a few percent of their citizens at most in the first couple months. The unvaccinated majority will still remain vulnerable to getting infected. A growing number of coronavirus vaccines are showing robust protection against becoming sick. But it’s also possible for people to spread the virus without even knowing they’re infected because they experience only mild symptoms or none at all. Scientists don’t yet know if the vaccines also block the transmission of the coronavirus. So for the time being, even vaccinated people will need to wear masks, avoid indoor crowds, and so on. Once enough people get vaccinated, it will become very difficult for the coronavirus to find vulnerable people to infect. Depending on how quickly we as a society achieve that goal, life might start approaching something like normal by the fall 2021.
    • If I’ve been vaccinated, do I still need to wear a mask? Yes, but not forever. Here’s why. The coronavirus vaccines are injected deep into the muscles and stimulate the immune system to produce antibodies. This appears to be enough protection to keep the vaccinated person from getting ill. But what’s not clear is whether it’s possible for the virus to bloom in the nose — and be sneezed or breathed out to infect others — even as antibodies elsewhere in the body have mobilized to prevent the vaccinated person from getting sick. The vaccine clinical trials were designed to determine whether vaccinated people are protected from illness — not to find out whether they could still spread the coronavirus. Based on studies of flu vaccine and even patients infected with Covid-19, researchers have reason to be hopeful that vaccinated people won’t spread the virus, but more research is needed. In the meantime, everyone — even vaccinated people — will need to think of themselves as possible silent spreaders and keep wearing a mask. Read more here.
    • Will it hurt? What are the side effects? The Pfizer and BioNTech vaccine is delivered as a shot in the arm, like other typical vaccines. The injection into your arm won’t feel different than any other vaccine, but the rate of short-lived side effects does appear higher than a flu shot. Tens of thousands of people have already received the vaccines, and none of them have reported any serious health problems. The side effects, which can resemble the symptoms of Covid-19, last about a day and appear more likely after the second dose. Early reports from vaccine trials suggest some people might need to take a day off from work because they feel lousy after receiving the second dose. In the Pfizer study, about half developed fatigue. Other side effects occurred in at least 25 to 33 percent of patients, sometimes more, including headaches, chills and muscle pain. While these experiences aren’t pleasant, they are a good sign that your own immune system is mounting a potent response to the vaccine that will provide long-lasting immunity.
    • Will mRNA vaccines change my genes? No. The vaccines from Moderna and Pfizer use a genetic molecule to prime the immune system. That molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse to a cell, allowing the molecule to slip in. The cell uses the mRNA to make proteins from the coronavirus, which can stimulate the immune system. At any moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce in order to make proteins of their own. Once those proteins are made, our cells then shred the mRNA with special enzymes. The mRNA molecules our cells make can only survive a matter of minutes. The mRNA in vaccines is engineered to withstand the cell’s enzymes a bit longer, so that the cells can make extra virus proteins and prompt a stronger immune response. But the mRNA can only last for a few days at most before they are destroyed.

Many of these rollout woes are caused by logistical issues — against the backdrop of a strained health care system and skepticism around vaccines. Freeing up more doses for first injections won’t solve problems like those, some researchers argue.

Shweta Bansal, a mathematical biologist at Georgetown University, and others also raised concerns about the social and psychological impacts of delaying second doses.

“The longer the duration between doses, the more likely people are to forget to come back,” she said. “Or people may not remember which vaccine that they got, and we don’t know what a mix and match might do.”

In an emailed statement, Dr. Peter Marks, director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, endorsed only the strictly scheduled two-dose regimens that were tested in clinical trials of the vaccines.

The “depth or duration of protection after a single dose of vaccine,” he said, can’t be determined from the research published so far. “Though it is quite a reasonable question to study a single-dose regimen in future clinical trials, we simply don’t currently have these data.”

The vaccine makers themselves have taken divergent positions.

In a trial of the Oxford-AstraZeneca vaccine, volunteers in Britain were originally intended to receive two doses given four weeks apart. But some vaccinated participants ended up receiving their doses several months apart, and still acquired some protection against Covid-19.

An extended gap between doses “gives you a lot of flexibility for how you administer your vaccines, dependent on the supply that you have,” said Menelas Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca.

Delayed dosing could help get countries “in very good shape for immunizing large swaths of their populations to protect them quickly.”

Steven Danehy, a spokesman for Pfizer, struck a far more conservative tone. “Although partial protection from the vaccine appears to begin as early as 12 days after the first dose, two doses of the vaccine are required to provide the maximum protection against the disease, a vaccine efficacy of 95 percent,” he said.

“There are no data to demonstrate that protection after the first dose is sustained after 21 days,” he added.

Ray Jordan, a spokesman for Moderna, said the company could not comment on altering dosing plans at this time.

There is no dispute that second doses should be administered sometime near the first dose. “They key is to expose the immune system at a time when it still recognizes” the immunity-stimulating ingredients in the vaccine, said Angela Rasmussen, a virologist affiliated with Georgetown University.

During a public health emergency, “companies will tend to pick the shortest period they can that gives them that full, protective response,” said Dr. Dean of the University of Florida.

But it’s unclear when that critical window really starts to close in the body. Akiko Iwasaki, an immunologist at Yale University who supports delaying second doses, said she thought the body’s memory of the first injection could last at least a few months.

Doses of other routine vaccines, she noted, are scheduled several months apart or even longer, to great success. “Let’s vaccinate as many people as possible now, and give them the booster dose when they become available,” she said.

Dr. Robert Wachter, an infectious disease physician at the University of California, San Francisco, said he was originally skeptical of the idea of delaying second doses.

But the disappointingly slow vaccine rollout in the United States, coupled with concerns about a new and fast-spreading variant of the coronavirus, have changed his mind, and he now believes this is a strategy worth exploring.

“The past couple weeks have been sobering,” he said.

Other researchers are less eager to take the gamble. Delaying doses without strong supporting data “is like going into the Wild West,” said Dr. Phyllis Tien, an infectious disease physician at the University of California, San Francisco. “I think we need to follow what the evidence says: two shots 21 days apart for Pfizer, or 28 days apart for Moderna.”

Some experts also fear that delaying an immunity-boosting second dose might give the coronavirus more opportunity to multiply and mutate in partly protected people.

There is some evidence to support the alternative strategy of halving the dose of each shot, suggested on Sunday by Mr. Slauoi of Operation Warp Speed.

In an interview on the CBS program “Face the Nation,” Dr. Slaoui pointed to data from clinical trials run by Moderna, whose vaccine is typically given in two doses, four weeks apart, each containing 100 micrograms of active ingredient.

In the trials, people between the ages of 18 and 55 who received two half-doses produced an “identical immune response to the 100 microgram dose,” Dr. Slaoui said. The F.D.A. and Moderna are now considering implementing this regimen on a more widespread scale, he added.

While there’s little or no data to support the soundness of delayed dose delays, Dr. Slaoui said, “injecting half the volume” might constitute “a more responsible approach that will be based on facts and data to immunize more people.”

But Dr. Dean and John Moore, a vaccine expert at Cornell University, both pointed out that this regimen would still represent a departure from the ones rigorously tested in clinical trials.

A half-dose that elicits an immune response that appears similar to that triggered by a full dose may not in the end deliver the expected protection against the coronavirus, Dr. Moore noted. Halving doses “is not something I would want to see done unless it were absolutely necessary,” he said.

“Everyone is looking for solutions right now, because there is an urgent need for more doses,” Dr. Dean said. “But the dust has not settled on the best way to achieve this.”

Categories
Politics

Group’s Lack of Hospital Stirs Contemporary Debate Over Indian Well being Service

Community’s Loss of Hospital Stirs Fresh Debate Over Indian Health Service

The hospital is operated nationwide by the Indian Health Service based in Rockville, Md. The agency was formed to meet the government’s contractual obligations to provide health services to eligible Alaskan Indians and natives.

Updated

Jan. 3, 2021, 1:42 AM ET

The Acoma Cañoncito Laguna service unit, 60 km west of Albuquerque, treats around 126,000 patients annually. Before the reduction in services, the company had 25 inpatient beds and looked after around 9,100 tribal citizens of the surrounding tribes. The hospital has been in operation since the mid-1970s and provides inpatient and outpatient care, as well as dental, optometric, pharmaceutical and medical emergency services.

Coronavirus cases for Acoma Pueblo, which has a population of around 3,000, have increased recently, including 100 in early November after no cases were reported in September.

The Albuquerque office is one of IHS ’12 service regions and serves 20 pueblos, two Apache bands, three Navajo chapters, and two Ute tribes in four southwestern states. There are five hospitals, 11 health centers and 12 field clinics serving the area’s residents.

Wendy Sarracino, 57, an Acoma community health worker, said when her son broke his leg, she had to stop at two hospitals before he could get the care he needed. At the time of his injury, the hospital of the Acoma Cañoncito Laguna service unit was already closed for that day, so Ms. Sarracino drove her son to Grants for 45 minutes.

After the hospital failed to diagnose the multiple fractures in her son’s legs, Ms. Sarracino drove him to Albuquerque for another hour. Grants Hospital found only a single fracture in her son’s leg, but an X-ray at Albuquerque Hospital found multiple fractures in both legs.

“That was kind of a lifeline,” Ms. Sarracino said of the hospital. “We didn’t have to go very far for health care. Awareness needs to be raised that the people of rural New Mexico live and that we need health care. “

Categories
Health

Who Ought to Get the Covid-19 Vaccine Subsequent? A Debate

Who Should Get the Covid-19 Vaccine Next? A Debate

Bazelon: We need them!

Ezike: Law. However, I think there is a possible problem with the long-term care population. Many of these people may still die for other reasons, but then the conclusion might be, “Grandma got the vaccine and died in the next week.” These are elderly people with comorbidities and their death coincides with time after vaccination but is not caused by the vaccine. However, I think this is going to be confusing for a lot of people. If health care workers get vaccinated and survive, people can gain the confidence to say, “OK, I’m ready now. I stand in line. “I think there will be this big push in the end when people say,” So far, so good. “

Gonsalves: If you follow Peter’s age-based utilitarianism, we should prioritize immunizing the people of the global south. Most of the young people on this planet live there.

Singer: I totally agree. Getting vaccines to the global south should be a very high priority.

Gonsalves: However, for now, most vaccinations are given in Europe, Australia, New Zealand, the UK, the US and Canada. The People’s Vaccine Alliance, which includes Amnesty International and Oxfam, just released a report that says that in 70 lower-income countries, only 1 in 10 people will have access to the vaccine by 2021. We are setting up some sort of medical apartheid in the next few months and even a few years where the virus will be under control in the US, Europe and some other places, but if you come from another country with no proof of immunity and trying to get a student visa to the US, good luck.

Ezike: Think more globally when I think of Nigeria, my father’s birthplace – access to vaccines, access to tests, all of that is limited there. We are not seeing a significant number of deaths in Nigeria and that is a godsend. But if broadcast were widespread, considering how many Nigerians travel overseas, there would be serious repercussions across national borders.

Bazelon: The rich countries seem to be planning to hoard vaccines. The European Union has ordered enough to immunize its residents twice. The UK and United States could each vaccinate four times if the supplies they set up are delivered, and Canada six times, according to a New York Times analysis of data on vaccination contracts. The World Health Organization and others have led an international initiative called Covax, which is providing a billion doses to less wealthy countries. But that’s not enough for a fair distribution.

Gonsalves: Here we go again, right? I mean, I am an epidemiologist. I am also an AIDS activist. And in 1996 a highly active antiretroviral therapy came out, and where did it go? It went to the industrialized north. And within a few years everyone around the world has been asking for it.

Mukherjee: Companies in India manufacture hundreds of millions of doses of Covid vaccines. China and Russia also have vaccines. However, we don’t know if any of these vaccines were tested with the same accuracy as the Pfizer and Moderna vaccines. For me, this is the most unfortunate thing about vaccine testing that has happened by far. The only data we have on the Chinese vaccine is from the United Arab Emirates and Bahrain, and we don’t know its effectiveness. They say it’s 86 percent; We don’t know real numbers. The Russian vaccine also released very little information. Then there is the AstraZeneca vaccine which has had data problems.

Categories
Business

What Is 13-3? Why a Debate Over the Fed Is Holding Up Stimulus Talks

What Is 13-3? Why a Debate Over the Fed Is Holding Up Stimulus Talks

When the markets collapsed in March, the Federal Reserve introduced novel programs to help keep the flow of credit to states, medium-sized businesses, and large corporations alive. Congress presented Treasury Secretary Steven Mnuchin $ 454 billion to support the effort.

Nine months later, Senate Republicans are trying to ensure the same programs cannot be restarted after Mr Mnuchin lets them end on December 31st. Aside from preventing their reincarnation under the Biden administration, Republicans are trying to fit language into a pandemic stimulus package that would limit the Fed’s future powers and potentially prevent it from lending to businesses and local authorities in future crises.

The last-minute move has drawn democratic anger and threatened the fate of relief laws, which economists believe are badly needed as households and businesses stare at a dark winter pandemic. Here’s an overview of how the Fed’s lending powers work, and how the Republicans are trying to change them.

The most important and well-known job of the Fed is to set interest rates as a guide for the economy. However, the central bank was founded in 1913 to avoid banking problems and financial panic – when people get nervous about the future and rush to withdraw their money from bank accounts and sell stocks, bonds, and other investments. Congress dramatically expanded the Fed’s powers to fight panic during the Great Depression, adding Section 13-3 to the Federal Reserve Act.

The section allows the Fed to act as the lender of last resort in “unusual and urgent” circumstances – in short, when markets are not functioning normally because investors are extremely concerned. The central bank used these powers extensively during the 2008 crisis to support politically unpopular bailouts for financial companies. Congress then changed the Fed’s powers to require the blessing of the Treasury Department to introduce new emergency loan programs or to make significant changes to existing programs.

During the 2008 crisis, the Fed served primarily as the true lender of last resort – it mainly assisted the various financial markets by offering to intervene when conditions got really bad.

The emergency loan programs for 2020 were far more extensive. Last time the Fed focused on parts of Wall Street that most Americans know little about, like the commercial paper market and primary dealers. This time these measures were reintroduced, but new programs were also introduced to keep credit available in almost all parts of the economy. It has offered to buy municipal bonds, support bank loans to small and medium-sized businesses, and buy up corporate debt.

The comprehensive package was an answer to a real problem: many markets crashed in March. And the new programs generally worked. Although the terms were not particularly generous and relatively few corporations, as well as state and local borrowers, have taken advantage of these new programs, their existence gave investors confidence that the central bank would prevent a financial collapse.

Most lawmakers agreed that the Fed and the Treasury Department did a good job of reopening credit markets and protecting the economy. But Senator Patrick J. Toomey, a Republican from Pennsylvania, began asking questions this summer about when the programs would end. He said he was concerned that the Fed could push its limits and replace private lenders.

After the election, other Republicans joined Mr Toomey’s push to end the programs. Mr Mnuchin announced on Nov. 19 that he believes that Congress is earmarked for the five programs backed by the $ 454 billion Congress, which has the power to regulate lending and bond purchases on Dec. December to discontinue. and asked the Fed to return the money he had loaned to the central bank.

Economy & Economy

Updated

Apr. 18, 2020 at 12:25 am ET

The Fed made a statement that it was dissatisfied with his election but agreed to return the money.

Democrats criticized the move to limit the possibilities of the new Biden government. They began to discuss whether they could reclaim the funds and restart the programs once Mr Biden took office and his finance minister was confirmed, as Mr Mnuchin’s decision to close them and reclaim the funds was based on dubious legal grounds.

The new Republican move would cut that option off. Legislative language circulated early Friday suggested “any program or facility similar to an established program or facility” be banned with the 2020 funds. While this would allow the Fed to continue providing liquidity to Wall Street during a crisis, it could continue to seriously limit the central bank’s freedom to lend to corporations, states and local governments.

In a statement, Massachusetts Democrat Senator Elizabeth Warren called it an attempt to “sabotage President Biden and our nation’s economy.”

Mr Toomey defended his proposal to protect the Fed from politicization. For example, he said Democrats could try to make the Fed’s programs much more generous to states and local governments.

The Treasury Secretary would need the approval of the Fed to improve conditions and help beneficiary borrowers. The central bank could not readily agree, however, as it has generally approached its powers cautiously to avoid political scrutiny and maintain its status as a bipartisan institution.

Fed officials have avoided incriminating the ongoing showdown in Congress.

“I will have nothing more to say about this than what we have already said – that Secretary Mnuchin, as Treasury Secretary, wants the programs to end by December 31,” and that the Fed will return the money as requested, Richard H. Clarida, who vice chairman of the Fed said Friday on CNBC.

More generally, he added that “we believe the 13-3 facilities” were “very valuable”.

Emily Cochrane contributed to coverage from Washington.

Categories
Business

Specialists Debate Biden’s Local weather Coverage Guarantees

Experts Debate Biden's Climate Policy Promises

The Biden government is faced with the daunting task of rebuilding international alliances that have frayed in recent years. Expect renewed global climate cooperation to happen quickly, both in prominent settings like the Paris Agreement and in quieter diplomatic efforts, said Rajiv Shah, president of the Rockefeller Foundation and former head of the U.S. Agency for International Development.

These diplomatic moves, “coupled with the running of large corporations and large financial institutions,” would be “a tremendous asset,” he said.

Economy & Economy

Updated

Apr. 11, 2020, 6:16 pm ET

In terms of the private sector, the financial industry could help realign government policy, said Ariel Meyerstein of Citi. “There’s an entirely different infrastructure out there in the financial sector that we’ve been reviewing for a couple of years,” he said. The government could help set standards for investors who pursue environment, society and governance (ESG) goals, he added. When it comes to corporate climate risk disclosure, it would have a bigger impact, he said:

“As we know, there is a dizzying range of standards in ESG and sustainability reporting. We could use alignment there. There are a lot of things that you can call Track II diplomacy or just regulatory engagement that happens in a very robust way in normal times and doesn’t require legislative or administrative action or executive orders or pronouncements. It’s just about coordinating with our colleagues around the world. I think all of this is pretty important. “

The mandatory disclosure of climate risks by publicly traded companies appears to be a “high priority” for the Biden administration, said Rostin Behnam, commissioner at the Commodity Futures Trading Commission. “That’s probably the first thing people think of when they think of climate change and the financial markets.” A new report from the CFTC clearly outlined the risk of climate change to financial stability and explained how the next government could use its findings:

“One of the strongest and most frequently quoted statements at the beginning of the report – which can be viewed or used as a starting point for Day 1 in a new administration – is that climate change is a major risk to the stability of the US Financial system. And I think that in itself will change the way financial regulators think about climate change. “

Categories
Business

Consultants Debate How To Put together For the Subsequent Pandemic

Experts Debate How To Prepare For the Next Pandemic

The Food and Drug Administration will hold a hearing this week to determine whether to grant emergency authorization to a coronavirus vaccine developed by Pfizer and BioNTech. The vaccine, which the companies claim is 95 percent effective, is one of two that could be ready for injections in the United States before the end of this year. The other, by Moderna, will be considered by the regulator for emergency approval next week. In early trials, the vaccine appeared to prevent the development of Covid-19 in around 94 percent of recipients.

The news is a welcome development in the otherwise grim saga of the fight against the coronavirus. The United States averages around 200,000 new cases each day, and more than 2,000 deaths.

An effective and widely available vaccine has long been promoted as the lifeline that will curb infections, save lives and pull a battered economy back from the brink. Yet the impending arrival of one or more vaccines raises questions about equity, education and how battered American institutions should prepare for the next pandemic, while repairing the damage wrought by this one.

As part of the DealBook D.C. Policy Project, The New York Times gathered a virtual panel of experts in early December to discuss the policy environment in a post-Covid world — or, at least, a post-Covid vaccine world.

The participants:

  • Ruth Faden, professor of bioethics at Johns Hopkins University

  • James E.K. Hildreth, professor of internal medicine, president and chief executive of Meharry Medical College

  • Marc Lipsitch, professor of epidemiology and director of the Center for Communicable Disease Dynamics at Harvard T.H. Chan School of Public Health

  • Thomas M. Moriarty, chief policy and external affairs officer and general counsel at CVS Health

  • Gregory A. Poland, professor of medicine and infectious diseases and director of the Vaccine Research Group at the Mayo Clinic

  • Monica Schoch-Spana, medical anthropologist and senior scholar with the Johns Hopkins Center for Health Security

  • Moderated by Carl Zimmer, The Times’s “Matter” columnist

An effective vaccine will be a huge breakthrough for society and the economy. But will it as effective in practice as in studies?

Gregory Poland of the Mayo Clinic, who is also editor in chief of the journal Vaccine, explained the extent to which early results of the various vaccine trials have defied even optimistic expectations. He described it as “as nothing short of dizzying,” and added:

“We were all prepared to see something like 50 to 70 percent efficacy, something like that. And to be in excess of 90 percent, 95 percent, puts it on par with the best vaccines that have ever been developed — and with apparent acceptable short-term safety. I think this is really going to have a profound effect on the field of vaccinology. I hate to overuse the word ‘paradigm-breaking,’ but it is, in many ways, to see something come to fruition within eight months like this.”

But Mr. Poland also warned of “surprises” when measuring the impact of the first generation vaccines:

“The efficacy measures we have were at times of relatively low transmission of disease compared to now. It was with masks on with people distanced, none of which will be true in time. So we may see some differences.”

Who should be first in line for the vaccinations? What’s fair when allocating a limited number of shots?

Even if vaccine injections are approved for use before the end of the year, the vast majority of people in the United States won’t notice any appreciable difference in their lives for at least three months, said Marc Lipsitch. Cases will continue to rise as winter temperatures force more people indoors, and there won’t yet be enough doses to cover the population.

That raises some thorny questions.

Earlier this month, the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention voted to vaccinate health care workers and nursing home residents first. It proposed placing essential workers like bus drivers and grocery workers in the next tier of recipients.

Mr. Lipsitch is among those who supports the alternative recommendation of the National Academies of Sciences, Engineering and Medicine to dole out the vaccine based on people’s health conditions rather than their working ones:

“The only certain way, given what we know about the vaccine now, to get society back to being able to function is to have this be a less-severe disease. And the way you do that is to make the people in whom it’s severe no longer vulnerable.”

But Mr. Lipsitch also acknowledged that the vaccine might never fully rid the world of Covid-19. “I can’t conceive of its disappearing,” he said. “Viral infections this widespread don’t disappear on their own that I’m aware of, unless they’re out-competed by some new strain.”

He suggested, however, that Covid-19 might become less severe in the long term. “If everybody essentially in the world who’s not a newborn has either had the virus or had the vaccine,” he said, “there would be some immunity to severity, and some immunity to transmission, and so if I had to make a guess I would say it would become a seasonal disease like the flu.”

Your neighborhood pharmacy will soon become a major player in vaccine distribution.

Getting a Covid-19 vaccine to millions of people in every corner of the country is, of course, a huge logistical undertaking. Rather than relying on public health networks, the Trump administration has placed the nation’s two largest for-profit pharmacy chains, CVS and Walgreens, at the center of the nation’s vaccination effort.

That also puts those chains at the forefront of an effort to educate the public about a new vaccine, and to convince the many skeptics that the rapidly developed shot is safe. Thomas Moriarty of CVS Health shared a little of what that task looks like, noting that about three-quarters of all Americans live within three miles of a CVS, “and we have the ability to extend beyond that through vaccination clinics.”

The Road to a Coronavirus Vaccine

Words to Know About Vaccines

Confused by the all technical terms used to describe how vaccines work and are investigated? Let us help:

    • Adverse event: A health problem that crops up in volunteers in a clinical trial of a vaccine or a drug. An adverse event isn’t always caused by the treatment tested in the trial.
    • Antibody: A protein produced by the immune system that can attach to a pathogen such as the coronavirus and stop it from infecting cells.
    • Approval, licensure and emergency use authorization: Drugs, vaccines and medical devices cannot be sold in the United States without gaining approval from the Food and Drug Administration, also known as licensure. After a company submits the results of  clinical trials to the F.D.A. for consideration, the agency decides whether the product is safe and effective, a process that generally takes many months. If the country is facing an emergency — like a pandemic — a company may apply instead for an emergency use authorization, which can be granted considerably faster.
    • Background rate: How often a health problem, known as an adverse event, arises in the general population. To determine if a vaccine or a drug is safe, researchers compare the rate of adverse events in a trial to the background rate.
    • Efficacy: The benefit that a vaccine provides compared to a placebo, as measured in a clinical trial. To test a coronavirus vaccine, for instance, researchers compare how many people in the vaccinated and placebo groups get Covid-19. Effectiveness, by contrast, is the benefit that a vaccine or a drug provides out in the real world. A vaccine’s effectiveness may turn out to be lower or higher than its efficacy.
    • Phase 1, 2, and 3 trials: Clinical trials typically take place in three stages. Phase 1 trials usually involve a few dozen people and are designed to observe whether a vaccine or drug is safe. Phase 2 trials, involving hundreds of people, allow researchers to try out different doses and gather more measurements about the vaccine’s effects on the immune system. Phase 3 trials, involving thousands or tens of thousands of volunteers, determine the safety and efficacy of the vaccine or drug by waiting to see how many people are protected from the disease it’s designed to fight.
    • Placebo: A substance that has no therapeutic effect, often used in a clinical trial. To see if a vaccine can prevent Covid-19, for example, researchers may inject the vaccine into half of their volunteers, while the other half get a placebo of salt water. They can then compare how many people in each group get infected.
    • Post-market surveillance: The monitoring that takes place after a vaccine or drug has been approved and is regularly prescribed by doctors. This surveillance typically confirms that the treatment is safe. On rare occasions, it detects side effects in certain groups of people that were missed during clinical trials.
    • Preclinical research: Studies that take place before the start of a clinical trial, typically involving experiments where a treatment is tested on cells or in animals.
    • Viral vector vaccines: A type of vaccine that uses a harmless virus to chauffeur immune-system-stimulating ingredients into the human body. Viral vectors are used in several experimental Covid-19 vaccines, including those developed by AstraZeneca and Johnson & Johnson. Both of these companies are using a common cold virus called an adenovirus as their vector. The adenovirus carries coronavirus genes.
    • Trial protocol: A series of procedures to be carried out during a clinical trial.

One of Mr. Moriarity’s biggest concerns is whether people will be willing to take the vaccine. His team surveys up to 7,000 people two to three times a week about what he called the “hesitancy rate,” he explained:

“What we have seen in the data since getting past the election, and with the efficacy results of these vaccines becoming public, is that the hesitancy rate is starting to drop. There’s still going to be a core element of hesitancy — no question about it — but getting past the politics and seeing the results of the science is helping alleviate some of that hesitancy.”

The country needs to re-establish trust in institutions, because pandemics are here to stay.

Much of the conversation about the coronavirus pandemic has focused, understandably, on “getting back to normal.” Yet the inescapable truth is that, in many ways, there is no going back to the world as it was before the coronavirus. In a global economy in which pathogens can spread more quickly than ever before, the question is not if there will be another global pandemic, but when.

Monica Schoch-Spana, a medical anthropologist who studies the ways communities respond to disaster, talked about what needed to be done to repair institutions that struggled during this crisis to clearly and effectively communicate with the public:

“This is about trust, and trust building, and processes of reconciliation. And that takes time. And during that time, we can improve our messaging and involve trusted messengers. But what we’re talking about is re-establishing trust in institutions. We have to build processes for that, and strengthen the ones that are already there.”

She said that efforts to persuade the public to accept the vaccine will have to include different messages targeted at different communities:

“There will be certain messages that resonate really well in Baltimore City among local Black communities that may not resonate well with rural frontier Hispanics in southeastern Idaho. So we have to have those very hyperlocal perspectives.”

When it comes to public health education, the messenger is at least as important as the message.

Black, Latino and Asian communities have disproportionately borne the brunt of coronavirus cases in the United States. And yet, thanks to a legacy of racism in the American medical system, many in those communities are particularly wary of receiving the vaccine. Black adults, in particular, have expressed higher rates of vaccine hesitancy than others in the United States, a wariness fueled by the historical example of forced injections, forced sterilizations, unethical experimentation and other acts administered in the name of public health.

Opposition to the vaccine within these communities is of particular concern to James Hildreth, an immunologist who spent decades on H.I.V. and AIDS research as a professor at Johns Hopkins before taking over in 2015 as president of Meharry Medical College, a historically Black medical school in Nashville. He discussed his experience with what works in public health education — and what does not. “We discovered that the messages were fine, but if the messenger is not trusted you’re wasting your time,” he said:

“So we identified trusted messengers in those communities. We empowered them with the information they needed. They needed to believe it first — and accept it first — and they were the ones that delivered the messages that turned out to be quite effective. So that’s the model we’ve adopted to try to engage and reach minority communities with the vaccine.”

We have to take care of the virus. Then we have to take care of everything else.

The vaccine is not the end of the pandemic recovery period, but the beginning. Once the virus is under control, the nation faces disarray: millions of people unemployed, communities shattered by the loss of businesses, a generation with a disrupted education and deepened systemic inequalities.

“The pandemic did more than just make us physically sick,” said Ruth Faden, a bioethicist. But she explained how this pain could become a catalyst for a better society:

“I think it’s possible to envision a way in which for some of these horrible gaps in access, and the consequences that are lifelong for people’s prospects for a decent life, there will be an effort to fix them, perhaps with some urgency. I have to hope that something like that will happen as a consequence of what we’ve all gone through — and if not, it will be profoundly depressing.”